Dysnatremia, vasopressin, atrial natriuretic peptide and mortality in patients with community-acquired pneumonia: Results from the german competence network CAPNETZ

Respiratory Medicine

Volumn 108, Issue 11, 2014, Pages 1696-1705

  Krüger, Stefan ^a   Ewig, Santiago ^b   Giersdorf, Sven ^c   Hartmann, Oliver ^c   Frechen, Dirk ^a   Rohde, Gernot ^d   Suttorp, Norbert ^e   Welte, Tobias ^f  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Augusta Kranken Anstalt   (Germany)

^c THERMO FISHER SCIENTIFIC   (Germany)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Community acquired pneumonia; Hyponatremia; Prognosis; Vasopressin

Indexed keywords

ANTIINFECTIVE AGENT; ATRIAL NATRIURETIC FACTOR; C REACTIVE PROTEIN; GLUCOSE; SODIUM; VASOPRESSIN; BIOLOGICAL MARKER; VASOPRESSIN DERIVATIVE;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BODY TEMPERATURE; CHRONIC KIDNEY DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DYSNATREMIA; ELECTROLYTE DISTURBANCE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART RATE; HOSPITAL ADMISSION; HUMAN; HYPERNATREMIA; HYPONATREMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; UREA BLOOD LEVEL; VIRUS INFECTION; AGED; BLOOD; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; EPIDEMIOLOGY; FACTUAL DATABASE; GERMANY; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PNEUMONIA; PREDICTIVE VALUE; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; DATABASES, FACTUAL; FEMALE; GERMANY; HUMANS; HYPERNATREMIA; HYPONATREMIA; MALE; MIDDLE AGED; PNEUMONIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SODIUM; VASOPRESSINS;

EID: 84922580333     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.09.014     Document Type: Article

References (38)

1. R.J. Anderson, H.-M. Chung, R. Kluge, and R.W. Schrier Hyponatremia: a prospective analysis of its epidemiology and the pathogenic role of vasopressin Ann Intern Med 102 1985 164 168
2. H.J. Adrogue, and N.E. Madias Hyponatremia N Engl J Med 342 2000 1581 1589
3. L. De Luca, L. Klein, and J.E. Udelson Hyponatremia in patients with heart failure Am J Cardiol 96 2005 19L 23L
4. M. Gheorghiade, W.T. Abraham, and N.M. Albert Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry Eur Heart J 28 2007 980 988
5. M. Gheorghiade, J.S. Rossi, and W. Cotts Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial Arch Intern Med 167 2007 1998 2005
6. L. Klein, C.M. O'Connor, and J.D. Leimberger Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study Circulation 111 2005 2454 2460
7. W.R. Kim, S.W. Biggins, and W.K. Kremers Hyponatremia and mortality among patients on the liver-transplant waiting list N Engl J Med 359 2008 1018 1026
8. J.M. Stormont, and C. Waterhouse Severe hyponatremia associated with pneumonia Metabolism 11 1962 1181 1186
9. M.D. Zilberberg, A. Exuzides, and J. Spalding Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study BMC Pulm Med 8 2008 16
10. V. Nair, M.S. Niederman, N. Masani, and S. Fishbane Hyponatremia in community-acquired pneumonia Am J Nephrol 27 2007 184 190
11. M.J. Fine, T.E. Auble, and D.M. Yealy A prediction rule to identify low-risk patients with community-acquired pneumonia N Engl J Med 336 1997 243 250
12. M. Gheorghiade, M.A. Konstam, and J.C. Burnett Jr. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials JAMA 297 2007 1332 1343
13. M. Gheorghiade, I. Niazi, and J. Ouyang Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial Circulation 107 2003 2690 2696
14. M.A. Konstam, M. Gheorghiade, and J.C. Burnett Jr. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 2007 1319 1331
15. R.W. Schrier, P. Gross, and M. Gheorghiade Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia N Engl J Med 355 2006 2099 2112
16. T. Welte, N. Suttorp, and R. Marre CAPNETZ - community-acquired pneumonia competence network Infection 32 2004 234 238
17. T.T. Bauer, S. Ewig, R. Marre, N. Suttorp, T. Welte THE CAPNETZ STUDY GROUP CRB-65 predicts death from community-acquired pneumonia J Intern Med 260 2006 93 101
18. W.S. Lim, M.M. van der Eerden, and R. Laing Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study Thorax 58 2003 377 382
19. H. Mauch, G. Marklein, and E. Kühnen Infektionen der tiefen Atemwege H. Mauch, R. Lütticken, S. Gatermann, Quality standards for microbiological diagnostic techniques for infectious diseases 2000 Urban & Fischer Verlag München
20. N.G. Morgenthaler, J. Struck, and M. Christ-Crain Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study Crit Care 9 2005 R37 R45
21. N.G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin Clin Chem 52 2006 112 119
22. J. Struck, N.G. Morgenthaler, and A. Bergmann Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients Peptides 26 2005 2500 2504
23. N.G. Morgenthaler, J. Struck, and B. Thomas Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma Clin Chem 50 2004 234 236
24. D. Dreyfuss, F. Leviel, M. Paillard, and F. Coste Resetting of the vasopressin osmostat during infectious pneumonia Am J Med 90 1991 407 408
25. D. Dreyfuss, F. Leviel, M. Paillard, J. Rahmani, and F. Coste Acute infectious pneumonia is accompanied by a latent vasopressin-dependent impairment of renal water excretion Am Rev Respir Dis 138 1988 583 589
26. S. Singhi, and A. Dhawan Frequency and significance of electrolyte abnormalities in pneumonia Indian Pediatr 29 1992 725 740
27. S. Krüger, S. Ewig, and J. Kunde Pro-vasopressin (copeptin) in patients with community-acquired pneumonia - influence of antibiotic pre-treatment J Antimicrob Chemother 64 2009 159 162
28. S. Krüger, J. Papassotiriou, and R. Marre Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia Intensive Care Med 33 2007 2069 2078
29. S. Krüger, S. Ewig, S. Giersdorf, O. Hartmann, N. Suttorp, T. Welte The CAPNETZ study group Cardiovascular and inflammatory biomarkers to predict short- and longt-term survival in community-acquired pneumonia. Results from the German competence network CAPNETZ Am J Respir Crit Care Med 182 2010 1426 1434
30. S. Krüger, S. Ewig, J. Kunde, O. Hartmann, N. Suttorp, T. Welte The CAPNETZ Study group Pro-atrial natriuretic peptide and pro-vasopressin to predict short- and long-term survival in community-acquired pneumonia. Results from the German competence network CAPNETZ Thorax 65 2010 208 214
31. S. Jochberger, V.D. Mayr, and G. Luckner Serum vasopressin concentrations in critically ill patients Crit Care Med 34 2006 293 299
32. S. Jochberger, N.G. Morgenthaler, and V.D. Mayr Copeptin and arginine vasopressin concentrations in critically ill patients J Clin Endocrinol Metab 91 2006 4381 4386
33. V.J. Dzau, M. Packer, L.S. Lilly, S.L. Swartz, N.K. Hollenberg, and G.H. Williams Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia N Engl J Med 310 1984 347 352
34. M. Packer, W.H. Lee, P.D. Kessler, N. Medina, M. Yushak, and S.S. Gottlieb Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure J Am Coll Cardiol 10 1987 837 844
35. M. Packer, N. Medina, and M. Yushak Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure J Am Coll Cardiol 3 1984 1035 1043
36. C.W. Yancy, M. Lopatin, L.W. Stevenson, T. De Marco, and G.C. Fonarow Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database J Am Coll Cardiol 47 2006 76 84
37. A.A. Mohammed, R.R. van Kimmenade, and M. Richards Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study Circ Heart Fail 3 2010 354 361
38. C.P. Kovesdy, E.H. Lott, and J.L. Lu Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure Circulation 125 2012 677 684